Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Inflammation or degeneration of the sensory nerves.
Biomarker and diagnostic research for sensory peripheral neuropathy has been reported in the published literature.
5 clinical trials registered. Interventions under study include drug therapy, other interventions, medical devices, and procedural interventions. Pipeline includes 1 PHASE4, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06605612](https://clinicaltrials.gov/study/NCT06605612) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders |
— |
LMU Klinikum |
ENROLLING_BY_INVITATION |
[NCT05483816](https://clinicaltrials.gov/study/NCT05483816) | MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts | NA | ETH Zurich | UNKNOWN |
[NCT06183008](https://clinicaltrials.gov/study/NCT06183008) | IVIG in Painful Sensory Neuropathy | PHASE4 | Sorlandet Hospital HF | NOT_YET_RECRUITING |
[NCT06078527](https://clinicaltrials.gov/study/NCT06078527) | Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort | NA | University of California, San Francisco | UNKNOWN |
[NCT07172763](https://clinicaltrials.gov/study/NCT07172763) | The Pressure Relieving Capacity of Siliconepads Compared to Felted Foam to Relieve Caput Metatarsal 2 in a Population With Diabetes | — | University Hospital, Ghent | UNKNOWN |
216 publications have been identified in PubMed for sensory peripheral neuropathy. Research spans Review / Meta-Analysis (32%), Clinical Trial Publication (22%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 69 | 32% |
Clinical study results | 48 | 22% |
Laboratory research | 34 | 16% |
Disease patterns and progression | 31 | 14% |
Patient case studies | 13 | 6% |
Testing and diagnosis research | 11 | 5% |
New treatment approaches | 7 | 3% |
Other research | 3 | 1% |
Mauermann ML (2026). [PMID: 41247746](https://pubmed.ncbi.nlm.nih.gov/41247746/). *JAMA*. [Review / Meta-Analysis]
Shang H (2026). [PMID: 41506491](https://pubmed.ncbi.nlm.nih.gov/41506491/). *Brain Behav Immun*. [Basic Science / Preclinical]
Malka-Gibor E (2026). [PMID: 41483810](https://pubmed.ncbi.nlm.nih.gov/41483810/). *Stem Cell Reports*. [Basic Science / Preclinical]
Sun J (2026). [PMID: 41539700](https://pubmed.ncbi.nlm.nih.gov/41539700/). *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi*. [Review / Meta-Analysis]
Fujii T (2026). [PMID: 41778252](https://pubmed.ncbi.nlm.nih.gov/41778252/). *Cancer Diagn Progn*. [Clinical Trial Publication]
Araujo Feitosa AC (2026). [PMID: 41569175](https://pubmed.ncbi.nlm.nih.gov/41569175/). *Asian Pac J Cancer Prev*. [Epidemiology / Natural History]
Wen H (2026). [PMID: 39651795](https://pubmed.ncbi.nlm.nih.gov/39651795/). *Expert Opin Drug Saf*. [Epidemiology / Natural History]
Kautzmann S (2026). [PMID: 41017721](https://pubmed.ncbi.nlm.nih.gov/41017721/). *Neural Regen Res*. [Basic Science / Preclinical]
Wintner LM (2026). [PMID: 41570841](https://pubmed.ncbi.nlm.nih.gov/41570841/). *Lancet Oncol*. [Clinical Trial Publication]
Bi J (2026). [PMID: 40222360](https://pubmed.ncbi.nlm.nih.gov/40222360/). *Acta Haematol*. [Clinical Trial Publication]
AI-curated news mentioning sensory peripheral neuropathy
Updated Feb 14, 2026
Recent research identifies mitochondrial energetic failure as a key factor in FLVCR1-related sensory neuropathy. This discovery could pave the way for targeted therapies addressing the underlying mitochondrial dysfunction.